Videos

Clinicians expand their discussion with a second patient case, highlighting similarities and differences between cases, and particular treatment algorithms that may be helpful.

Experts continue their discussion of the first patient case, explaining how glutamate-modulating therapies could help improve his symptoms and outcomes.

Experts use a major depressive disorder (MDD) patient case to provide clinical insights on managing MDD, and how they would educate patients about their condition.

Don't miss this ACNP 2023 Annual Meeting session!

Clinicians wrap up their discussion of three new agents approved for the treatment of major depressive disorder (MDD).

Clinicians continue their discussion of three new agents approved for the treatment of major depressive disorder (MDD).

Clinicians begin their review of three new agents approved for the treatment of major depressive disorder (MDD).

"You will love again the stranger who was your self."

Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.

Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.

Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.

Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.

Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.

Who helped your career?

Clinicians discuss the effects of glutamate modulation on neuroplasticity, memory, and cognitive function, highlighting their role in improving overall wellness for their patients.

Experts highlight the role of NMDA and AMPA receptors in major depressive disorder (MDD) and how new therapies are targeting novel mechanisms of action.

Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.

Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.

"Hat factories closed quiet as prayer books, and loss lingered in my father’s guts like unswept garbage after a big parade..."

Who in your life are you grateful for?

"Perhaps the world will end at the kitchen table, while we are laughing and crying, eating of the last sweet bite."

Be kind!

How do you respond to change? What does properly adjusting to change acquire?

"Of her choice virtues only gods should speak, Or English poets who grew up on Greek (I’d have them sing in chorus, cheek to cheek)."

We need psychiatrists now more than ever...

"I know I have the blood of survivors coursing through my veins; I know the lament of our loss must warm us again and again down in the belly of the whale..."

Let's try to make the world a better place.

Gepirone, the first and only oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults, is expected to arrive in early 2024.

"His wing Scythes down another day, his motion Is that of the honed steel-edge, we hear The crashless fall of stalks of Time."

Roger S. McIntyre, MD, FRCPC, and Carmen Kosicek, MSN, PMHNP-BC, discuss the future of MDD treatment and share closing thoughts.